BPC-157 Dosage: Routes, Ranges & the Human-Data Gap
A third-person research reference on how BPC-157 was dosed in the published literature: the intraperitoneal, per-oral, intramuscular and topical routes and the microgram-to-nanogram-per-kilogram ranges reported in rodent healing studies, the rat-and-dog pharmacokinetic profile, and the single two-subject human intravenous safety pilot. BPC-157 has no validated human dose and is not an approved medicine.
Update History ▾
BPC-157 has no validated human dose and is not an approved medicine in any jurisdiction. Essentially every number that circulates as "BPC-157 dosing" comes from rodent injury studies — a literature dominated by a single research group in Zagreb — in which the peptide was given by intraperitoneal injection, in drinking water, intramuscularly, or as a topical cream at magnitudes on the order of micrograms to nanograms per kilogram of body weight.[1][5][6] The only human data of any kind is a 2025 two-subject intravenous safety pilot that gave two consecutive-day infusions ascending to 20 mg and measured tolerability, not efficacy.[7] This page summarizes what the literature reported, in the third person and for research context only; it is not a dosing protocol, and no figure here is a human-use instruction. For BPC-157's identity, chemistry and proposed mechanism, see the companion BPC-157 healing research review.
How BPC-157 Was Dosed in Animal Studies
Almost the entire BPC-157 dosing record is preclinical. The peptide's identity, chemistry and proposed nitric-oxide and VEGF healing mechanism are covered in the companion BPC-157 healing research review; this page stays on the narrower question of how it was actually administered. Across the rodent corpus — which spans tendon, ligament, muscle, vascular and pharmacokinetic studies — four administration routes recur.[1][2][3][8]
- Intraperitoneal (IP) injection. The most common route in the Zagreb injury models. In the rat Achilles-tendon-transection study, the peptide was given once daily intraperitoneally at 10 micrograms, 10 nanograms or 10 picograms per kilogram of body weight.[2]
- Per-oral, in drinking water. The rat medial-collateral-ligament study delivered the peptide in the drinking water at 0.16 micrograms per millilitre (about 12 ml per rat per day) as an alternative to injection.[1]
- Topical cream. The same ligament study also applied it locally as a thin cream layer (1.0 microgram dissolved per gram of neutral cream) at the injury site, and the muscle-crush study used a comparable topical-cream arm.[1][3]
- Intravenous and intramuscular. The first dedicated pharmacokinetic study dosed rats and beagle dogs by single intravenous and single or repeated intramuscular injection, reporting an elimination half-life under 30 minutes and intramuscular bioavailability of roughly 14–19% in rats and 45–51% in dogs.[4]
Reviews that summarize the whole corpus describe the effective magnitudes as broadly on the order of micrograms to nanograms per kilogram — most often cited around 10 µg/kg and 10 ng/kg — rather than as a single standardized dose.[5][6] Exact figures were not reported uniformly across every study, and the units are not directly comparable between routes (per-kilogram injections versus per-millilitre drinking water versus per-gram cream). Critically, these are rodent and canine figures; the reviews are explicit that they do not translate cleanly onto a human milligram scale, and this page makes no attempt to convert them.[9]
| Study model | Route(s) reported | Duration | Reported outcome | Source |
|---|---|---|---|---|
| Rat Achilles tendon transection | Intraperitoneal, once daily (10 µg / 10 ng / 10 pg per kg) | Assessed to day 14 | Accelerated tendon healing; improved biomechanics & function | PMID 14554208 |
| Rat medial collateral ligament transection | Intraperitoneal, per-oral (drinking water), topical cream | Throughout 90 days | Improved ligament healing across all three routes | PMID 20225319 |
| Rat gastrocnemius muscle crush | Intraperitoneal or topical cream, once daily | 14 days | Improved muscle healing; less haematoma & oedema | PMID 18668315 |
| Pharmacokinetics (rat & beagle dog) | Intravenous & intramuscular (single and repeated) | Single-dose PK window | Elimination half-life <30 min; IM bioavailability ~14–19% (rat), ~45–51% (dog) | PMC9794587 |
The Only Human Dosing Data
Until 2025, BPC-157 had no published human pharmacology of any kind. Lee and Burgess narrowed that gap with a two-subject intravenous pilot in healthy adults, published in 2025 and indexed at PMID 40131143.[7]
The study administered two consecutive-day intravenous infusions to two healthy adult participants — ascending from 10 mg on day 1 to 20 mg on day 2 — as a safety-and-tolerability assessment, with no efficacy endpoint. With only two participants it cannot characterise rare adverse events, dose-response, or human pharmacokinetics; what it establishes is that a first published human safety touchpoint now exists.[7]
For research-context framing, that two-day ascending infusion to 20 mg is the only human "dose" that appears anywhere in the peer-reviewed BPC-157 record. It is not a validated human dose, not a sustained-dosing regimen, and not a route comparison. Any source presenting a specific milligram-per-day human BPC-157 schedule is extrapolating well beyond this two-subject report.
Reconstitution & Handling (Research Use)
Because there is no human dose to describe, the only handling context this page provides is in-vitro laboratory handling of the research vial — not an administration protocol. BPC-157 ships as a lyophilized powder in a sealed vial, and the standard laboratory pattern is straightforward:
- Storage of the lyophilized vial. Held at 2–8 degrees Celsius and protected from light; frozen for longer-term storage, avoiding repeated fridge-to-bench temperature cycling.
- Reconstitution. Reconstituted with bacteriostatic water at the volume dictated by the research protocol, adding the diluent down the inner wall of the vial and letting it dissolve passively rather than shaking. The reconstitution calculator documents the concentration math (mass in the vial divided by diluent volume gives the label concentration).
- Post-reconstitution storage. Held at 2–8 degrees Celsius and used within the research-protocol window.
This describes the format and stability of the research vial and the arithmetic of label concentration; it is not a dosing instruction. The concentration a lab reconstitutes to is a handling choice, and the controlling reference for what is done with the reconstituted material is the investigator's own approved research protocol. BPC-157 is supplied strictly for in-vitro laboratory research and is not framed for human or veterinary use.
Why There Is No Established Human Dose
Four structural features of the evidence base explain why no validated human BPC-157 dose exists.
- The corpus is preclinical and single-group-dominated. The large majority of BPC-157 studies are rodent injury models, and a substantial share originate from one research group in Zagreb. Independent 2025 reviews summarising the literature reach the same conclusion — the peptide remains investigational, with the preclinical signal outpacing the human evidence.[9][10]
- No completed human efficacy RCT has been published. Early-2000s papers describe BPC-157 (as Pliva's PL-14736 / PLD-116) entering clinical trials for inflammatory bowel disease, but no completed efficacy randomised controlled trial from that development program has appeared in the peer-reviewed literature.[1] That history is a development footnote, not evidence of an established dose.
- There is no human pharmacokinetic profile. Half-life, distribution, and route-specific bioavailability in humans are not characterised; the only dedicated pharmacokinetic work is the rat-and-dog study, which reported an elimination half-life under 30 minutes.[4] Rodent per-kilogram figures cannot be scaled to a human milligram dose on that basis.
- It is not approved. BPC-157 is not approved as a medicine by any regulator, and recent independent reviews additionally flag that its long-term human safety is simply unknown.[10]
The through-line is consistent with the rest of this page: a real and reproducible preclinical dosing record, a single two-subject human safety touchpoint, and no basis for a validated human dose. Sources publishing specific human "BPC-157 protocols" are going beyond what the literature supports.
BPC-157 Research-Use Supply & Format
For research use, BPC-157 is supplied as a 10 mg lyophilized vial with cold-chain handling, reconstituted with bacteriostatic water for in-vitro work and with the active lot reference confirmed before dispatch — a format that mirrors how investigators handled the peptide in the animal-model literature, with no human-use framing attached.
The BPC-157 10mg research vial page documents the catalog format, current pricing, COA status and dispatch windows. Labs running BPC-157 alongside thymosin beta-4 / TB-500 typically reference the BPC-157 + TB-500 blend vial and the BPC-157 vs TB-500 comparison; the parallel dosing questions for that peptide are covered in the TB-500 dosage reference. Each BPC-157 research vial is supplied at >99% HPLC purity, and the standard reconstitution math sits in the reconstitution calculator.
Our Research Standards
This article prioritizes primary preclinical literature and peer-reviewed reviews, with every dose and route reported in the third person as it appeared in the cited study. Where the human dosing record is thin or absent, we say so directly. No therapeutic, human-use, or veterinary-use claim is made here. Read our editorial policy →
BPC-157 Research FAQ
Is there an established BPC-157 dosage?
No. There is no validated human BPC-157 dosage, and BPC-157 is not an approved medicine in any jurisdiction. Nearly all of the dosing figures that circulate come from rodent injury studies, where the peptide was given by intraperitoneal injection, in drinking water, intramuscularly, or as a topical cream at microgram-to-nanogram-per-kilogram magnitudes. The only human data of any kind is a 2025 two-subject intravenous safety pilot that measured tolerability, not efficacy (PMID 40131143). This page reports those figures in the third person for research context and does not provide a human-use dose.
What doses were used in BPC-157 studies?
Reported doses are from animals and are on the order of micrograms to nanograms per kilogram of body weight, most often cited around 10 micrograms per kilogram and 10 nanograms per kilogram. For example, the rat Achilles-tendon study gave 10 micrograms, 10 nanograms, or 10 picograms per kilogram intraperitoneally once daily (PMID 14554208), and the rat ligament study used 10 micrograms or 10 nanograms per kilogram intraperitoneally, 0.16 micrograms per millilitre in drinking water, and a 1.0 microgram-per-gram topical cream (PMID 20225319). Reported routes across the corpus include intraperitoneal, per-oral, intramuscular, and topical application. These are rodent figures and were not standardized across studies.
Has BPC-157 been dosed in humans?
Only once in the published literature. Lee and Burgess reported a two-subject intravenous pilot in healthy adults in 2025, giving two consecutive-day infusions ascending to 20 milligrams and assessing safety and tolerability with no efficacy endpoint (PMID 40131143). Two subjects cannot characterise rare adverse events, dose-response, or pharmacokinetics, and there is no published human pharmacokinetic profile and no registered Phase 2 or Phase 3 trial.
How is BPC-157 reconstituted for research?
For in-vitro research, lyophilized BPC-157 is reconstituted with bacteriostatic water at the volume dictated by the research protocol, stored at 2-8 degrees Celsius and protected from light. This is laboratory handling, not a dosing protocol: the reconstitution calculator documents the standard concentration math, and the bacteriostatic water guide covers the diluent.
Is BPC-157 approved?
No. BPC-157 is not approved as a medicine by any regulator and is supplied strictly for in-vitro laboratory research. Independent 2025 reviews classify it as investigational, citing an absence of registered human efficacy trials and an unresolved rodent-to-human dose-translation question (PMC12446177, PMC11859134).
Do the animal doses translate to a human dose?
No. The reviews are explicit that rodent microgram-to-nanogram-per-kilogram figures do not convert cleanly onto a human milligram scale, and the only dedicated pharmacokinetic study — in rats and beagle dogs — reported an elimination half-life under 30 minutes with no human pharmacokinetic data (PMC9794587). Any source publishing a specific human BPC-157 protocol is going beyond the published data.
Sources
- Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. PMID: 20225319 ↩
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PMID: 14554208 ↩
- Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716-725. PMID: 18668315 ↩
- He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PMC: PMC9794587 ↩
- Seiwerth S, et al. BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972-1989. PMID: 29998800 ↩
- Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PMID: 30915550 ↩
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20-24. PMID: 40131143 ↩
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID: 27847966 ↩
- McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMC: PMC12446177 ↩
- Józwiak M, et al. Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals (Basel). 2025;18. PMC: PMC11859134 ↩
For product-format details, see the BPC-157 10mg research vial and the BPC-157 + TB-500 blend. For the evidence split between the two repair-signalling lanes, read the BPC-157 vs TB-500 research comparison. For handling and compliance context, continue to the reconstitution guide and the COA library.